Erratum (DOI:10.1053/j.seminoncol.2009.06.008);Other Targetable Sarcomas

Seminars in Oncology

Volumn 36, Issue 4, 2009, Pages 358-371

  Pires de Camargo, Veridiana ^a   van de Rijn, Matt ^b   de Alava, Enrique ^c   Madoz Gúrpide, Juan ^c   Pilotti, Silvana ^d   von Mehren, Margaret ^e   Pedeutour, Florence ^f   Maki, Robert G ^a   Rutkowski, Piotr ^g   Thomas, David M ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d IRCCS   (Italy)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADW 742; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLIN DEPENDENT KINASE 4; DOCETAXEL; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IMATINIB; MITOMYCIN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN MDM2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG;

ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; ANGIOSARCOMA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHORDOMA; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE MARKER; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HEMANGIOPERICYTOMA; HUMAN; KAPOSI SARCOMA; LEIOMYOSARCOMA; LIPOSARCOMA; MYXOSARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SARCOMA; SKIN TOXICITY; SOLITARY FIBROUS TUMOR; SYNOVIAL SARCOMA; UNSPECIFIED SIDE EFFECT;

EID: 67949108223     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.09.001     Document Type: Erratum

References (83)

1. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
2. Grosso F., Jones R.L., Demetri G.D., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8 (2007) 595-602
3. Schöffski P., Casali P.G., Taron M., et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743) [abstract]. J Clin Oncol. 24 (2006) 9522
4. Espinosa I., Lee C.H., Kim M.K., et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 32 (2008) 210-218
5. Liegl B., Hornick J.L., Corless C.L., et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 33 (2009) 437-446
6. West R.B., Corless C.L., Chen X., et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 165 (2004) 107-113
7. Terry J., Saito T., Subramanian S., et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol. 31 (2007) 240-246
8. Dhanasekaran S.M., Dash A., Yu J., et al. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 19 (2005) 243-245
9. Higgins J.P., Kaygusuz G., Wang L., et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 31 (2007) 673-680
10. Yao R., Lopez-Beltran A., Maclennan G.T., et al. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 27 (2007) 3051-3058
11. Dabbs D.J., Chivukula M., Carter G., et al. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 19 (2006) 1506-1511
12. West R.B., Rubin B.P., Miller M.A., et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103 (2006) 690-695
13. Blay J.Y., El Sayadi H., Thiesse P., et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 19 (2008) 821-822
14. Tamimi R.M., Brugge J.S., Freedman M.L., et al. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 68 (2008) 18-21
15. Kovacheva V.P., Davison J.M., Mellott T.J., et al. Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. FASEB J. 23 (2009) 1054-1063
16. Beck A.H., Espinosa I., Gilks C.B., et al. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest. 88 (2008) 591-601
17. Cheang M.C., van de Rijn M., and Nielsen T.O. Gene expression profiling of breast cancer. Annu Rev Pathol. 3 (2008) 67-97
18. West R.B., Nuyten D.S., Subramanian S., et al. Determination of stromal signatures in breast carcinoma. PLoS Biol. 3 (2005) e187
19. Lee C.H., Espinosa I., Vrijaldenhoven S., et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 14 (2008) 1423-1430
20. Gygi S.P., Rochon Y., Franza B.R., et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 19 (1999) 1720-1730
21. Lu P., Vogel C., Wang R., et al. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol. 25 (2007) 117-124
22. Aebersold R., and Mann M. Mass spectrometry-based proteomics. Nature 422 (2003) 198-207
23. Yates III J.R., Gilchrist A., Howell K.E., et al. Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Biol. 6 (2005) 702-714
24. Ong S.E., and Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol. 1 (2005) 252-262
25. Cox J., and Mann M. Is proteomics the new genomics?. Cell 130 (2007) 395-398
26. Izbicka E., Campos D., Marty J., et al. Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models. Anticancer Res. 26 (2006) 1983-1988
27. Gonzalez I., Andreu E.J., Panizo A., et al. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res. 10 (2004) 751-761
28. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 (2004) 505-518
29. Mateo-Lozano S., Tirado O.M., and Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 22 (2003) 9282-9287
30. Scotlandi K., Benini S., Sarti M., et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 56 (1996) 4570-4574
31. Scotlandi K., Manara M.C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65 (2005) 3868-3876
32. Martins A.S., Mackintosh C., Martin D.H., et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 12 (2006) 3532-3540
33. Martins A.S., Ordonez J.L., Garcia-Sanchez A., et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 68 (2008) 6260-6270
34. Kovar H., Aryee D., and Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol. 11 (1999) 275-284
35. Cohen P. The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem Sci. 25 (2000) 596-601
36. Armistead P.M., Salganick J., Roh J.S., et al. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 110 (2007) 2293-2303
37. Casali P.G., Messina A., Stacchiotti S., et al. Imatinib mesylate in chordoma. Cancer 101 (2004) 2086-2097
38. Lagonigro M.S., Tamborini E., Negri T., et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol. 208 (2006) 615-623
39. Li Y., Chang Q., Rubin B.P., et al. Insulin receptor activation in solitary fibrous tumours. J Pathol. 211 (2007) 550-554
40. Liegl B., Gully C., Reich O., et al. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology 50 (2007) 448-452
41. McArthur G.A., Demetri G.D., van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 23 (2005) 866-873
42. Rubin B.P., Schuetze S.M., Eary J.F., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 20 (2002) 3586-3591
43. Signoroni S., Frattini M., Negri T., et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 13 (2007) 5034-5040
44. Tamborini E., Bonadiman L., Albertini V., et al. Re: potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. [letter]. J Natl Cancer Inst. 95 (2003) 1087-1088
45. Tamborini E., Bonadiman L., Greco A., et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res. 10 (2004) 938-943
46. Tamborini E., Casieri P., Miselli F., et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol. 212 (2007) 227-235
47. Tamborini E., Miselli F., Negri T., et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res. 12 (2006) 6920-6928
48. Heinrich M.C., Joensuu H., Demetri G.D., et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 14 (2008) 2717-2725
49. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100 (2002) 623-626
50. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
51. Azizi A.A., Haberler C., Czech T., et al. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 7 (2006) 521-523
52. Lazar A.J., Das P., Tuvin D., et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res. 13 (2007) 7314-7321
53. Tsuda M., Davis I.J., Argani P., et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 67 (2007) 919-929
54. Sirvent N., Coindre J.M., Maire G., et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 31 (2007) 1476-1489
55. Italiano A., Cardot N., Dupre F., et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas?. Int J Cancer 121 (2007) 308-315
56. Mandahl N., Akerman M., Aman P., et al. Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors: a report of the CHAMP collaborative study group. CHromosomes And MorPhology. Int J Cancer 67 (1996) 632-635
57. Mandahl N., Heim S., Johansson B., et al. Lipomas have characteristic structural chromosomal rearrangements of 12q13-q14. Int J Cancer 39 (1987) 685-688
58. Storlazzi C.T., Mertens F., Domanski H., et al. Ring chromosomes and low-grade gene amplification in an atypical lipomatous tumor with minimal nuclear atypia. Int J Oncol. 23 (2003) 67-71
59. Italiano A., Bianchini L., Keslair F., et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122 (2008) 2233-2241
60. Ambrosini G., Sambol E.B., Carvajal D., et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26 (2007) 3473-3481
61. Merks R.M., Perryn E.D., Shirinifard A., et al. Contact-inhibited chemotaxis in de novo and sprouting blood-vessel growth. PLoS Comput Biol. 4 (2008) e1000163
62. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285 (1971) 1182-1186
63. Folkman J. Successful treatment of an angiogenic disease. N Engl J Med. 320 (1989) 1211-1212
64. Ribatti D., Conconi M.T., and Nussdorfer G.G. Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev. 59 (2007) 185-205
65. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
66. Tobe T., Ortega S., Luna J.D., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 153 (1998) 1641-1646
67. Zhou M., Sutliff R.L., Paul R.J., et al. Fibroblast growth factor 2 control of vascular tone. Nat Med. 4 (1998) 201-207
68. Lindahl P., Johansson B.R., Leveen P., et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 (1997) 242-245
69. Urness L.D., Sorensen L.K., and Li D.Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 26 (2000) 328-331
70. Whitehead K.J., Plummer N.W., Adams J.A., et al. Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations. Development 131 (2004) 1437-1448
71. Dezube B.J., Von Roenn J.H., Holden-Wiltse J., et al., AIDS Clinical Trial Group No. 215 Team. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. J Clin Oncol. 16 (1998) 1444-1449
72. Baker L.H., Rowinsky E.K., Mendelson D., et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 26 (2008) 5583-5588
73. D'Adamo D.R., Anderson S.E., Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 23 (2005) 7135-7142
74. Keohan M.L., Morgan J.A., D'Adamo D.R., et al. Continuous daily dosing of sunitinib in patients with metastatic soft tissue sarcomas other than GIST: results of a phase II trial [abstract]. J Clin Oncol. 26 (2008) 10533
75. Sleijfer S., Papai Z., Le Cesne A., et al. Phase II study of pazopanib (GW786034) in patients with relapsed or refractory soft tissue sarcoma: EORTC 62043. [abstract]. J Clin Oncol. 25 (2007) 10031
76. D'Adamo D.R., Keohan M., Schuetze S., et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). [abstract]. J Clin Oncol. 25 (2007) 10001
77. Fata F., O'Reilly E., Ilson D., et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86 (1999) 2034-2037
78. Skubitz K.M., and Haddad P.A. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104 (2005) 361-366
79. Penel N., Bui B.N., Bay J.O., et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 26 (2008) 5269-5274
80. Fury M.G., Antonescu C.R., Van Zee K.J., et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 11 (2005) 241-247
81. Weenink J.J., Groeneveld J.O., and de Fijter C.W. Sirolimus monotherapy for Kaposi's sarcoma in an HIV-negative patient. Lancet Oncol. 7 (2006) 875-876
82. Sodhi A., Chaisuparat R., Hu J., et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10 (2006) 133-143
83. Stacchiotti S., Tamborini E., Marrari A., Brich S., Arisi Rota S., Orsenigo M., et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 15 (2009) 1096-1104